

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

CHANGE OF JOINT COMPANY SECRETARY AND AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND NOTICES IN HONG KONG

The board of directors (the “**Board**”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) hereby announces that Ms. MOK Ming Wai (莫明慧) (“**Ms. Mok**”) has resigned to serve as the joint company secretary and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) due to work re-allocation, with effect from 26 October 2018. Ms. Mok has confirmed that there is no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company in relation to her resignation.

The Board is pleased to further announce that Ms. LEUNG Suet Wing (梁雪穎) (“**Ms. Leung**”) has been appointed by the Company as a joint company secretary of the Company and the Process Agent, with effect from 26 October 2018. Mr. LIU Dawei (劉大偉) (“**Mr. Liu**”) will continue to serve as the other joint company secretary of the Company.

Ms. Leung, is an assistant manager of TMF Hong Kong Limited, which is a corporate secretarial services provider. She has over 7 years of professional experience in the company secretarial field. She is a member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Rules Governing the Listing of the Securities on the of the Stock Exchange (the “**Listing Rules**”), for a period from 26 October 2018 to 27 June 2019 in relation to Mr. Liu’s eligibility to act as the joint company secretary on the condition that Mr. Liu would be assisted by Ms. Leung to acquire the “relevant experience” within the meaning of Rule 3.28(2) of the Listing Rules to discharge his duties as joint company secretary of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Mok for her valuable contribution to the Company during her tenure as a joint company secretary and the

Process Agent of the Company, and to express its welcome to Ms. Leung on her appointment as a joint company secretary and the Process Agent of the Company.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHOU Jun
Chairman

Shanghai, the PRC, 27 October 2018

As at the date of this announcement, the executive directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive directors are Mr. ZHOU Jun and Ms. LI An; and the independent non-executive directors are Mr. WAN Kam To, Mr. TSE Cho Che, Edward, Mr. CAI Jiangnan and Mr. HONG Liang.

** For identification purpose only*